ADARx Pharmaceuticals is pursuing an IPO to raise capital for its RNA-targeted therapy pipeline, focusing on serious liver and non-liver diseases. Its lead drug, Onvuzosiran, is in Phase 3 trials for hereditary angioedema, with key data expected by the end of 2027 and a potential new drug application in 2028. The company has strong financial backing from a major collaboration with AbbVie, which includes upfront payments and milestone-based funding totaling billions. Supported by top venture capitalists and experienced management, ADARx aims to attract institutional investors if IPO pricing is favorable.
RH is set to report Q2 2026 earnings facing challenges from a weak housing market and international expansion expenses. Analysts expect earnings per share to fall significantly to between $0.38 and $0.46, down from $2.93 last year, despite a slight r...
Chewy reported Q2 results largely in line with expectations, with net sales up 7.3% to $3.33 billion and adjusted earnings matching forecasts at $0.36 per share. However, shares fell 10.8% due to concerns about slowing organic growth, cautious consum...
Macy's reported Q1 earnings per share of $0.40, exceeding the $0.37 estimate, with revenue of $4.87 billion beating expectations. Growth was driven by strong sales in Bloomingdale's, Bluemercury, and Macy's stores. The company raised its full-year ne...
Tyson Foods faces operational challenges, especially in its beef segment, leading Piper Sandler to cut its price target from $78 to $66. The company lowered its 2026 revenue growth forecast to 1.5%-2% and expects a beef segment operating loss between...
Descartes Systems Group is set to release its Q2 2027 earnings with analysts expecting $0.57 EPS and $197.54 million revenue. The company recently acquired Extensiv for $120 million, enhancing its warehouse and fulfillment solutions for e-commerce an...
